vimarsana.com

Latest Breaking News On - Company decoy - Page 1 : vimarsana.com

Indaptus Therapeutics (INDP) Presents Positive Mechanism of Action Data

Indaptus Therapeutics (INDP) Presents Positive Mechanism of Action Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
American
Michael-newman
Jeffrey-meckler
Company-decoy
Indaptus-therapeutics-inc
Nasdaq
Indaptus-therapeutics
American-association
Cancer-research
San-diego
Indaptu-founder

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
American
Michael-newman
Louie-toma
Jeffrey-meckler
Jules-abraham
Nasdaq
Indaptus-therapeutics-inc
Company-decoy
Fight-tumors-directly
American-association
Cancer-research

European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biopharma company that utilizes a propr.

United-states
Jeffrey-meckler
Louie-toma
Jules-abraham
European-patent-office
Nasdaq
Indaptus-therapeutics-inc
Company-decoy
Infections-using-bacteria
Indaptus-therapeutics
Private-securities-litigation-reform
Quarterly-report

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. “We have recently announced the completion of the first cohort of patients in our INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors and receipt of authorization from the Safety Review Committee to advance into the second cohort. As previously announced,

United-states
India
Boston
Massachusetts
Brazil
American
Louie-toma
Michael-newman
Roger-waltzman
Jules-abraham
Jeffrey-meckler
Nasdaq

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating

Data presented were crucial to initiating its ongoing Phase 1 clinical trial with Decoy 20 in solid tumors.

United-states
American
Michael-newman
Louie-toma
Jules-abraham
Michaelj-newman
Indaptus-therapeutics-inc
Company-founder
Company-decoy
American-association-for-cancer-research
Nasdaq
American-association

vimarsana © 2020. All Rights Reserved.